| [1] |
Calvert PM, Frucht H. The genetics of colorectal cancer [J]. Ann Inter Med, 2002, 137(7):603-612.
|
| [2] |
Kimelman D, Xu W. Beta-catenin destruction complex: insights and questions from from a structural perspective [J]. Oncogene, 2006, 25(57):7482-7491.
|
| [3] |
Martensson A, Oberg A, Jung A, et al. Beta-catenin expression in relation to genetic instability and prognosis in colorectal cancer [J]. Oncology reports, 2007, 17(2):447-452.
|
| [4] |
Wanitsuwan W. Overall expression of beta-catenin outperforms its nuclear accumulation in predicting outcomes of colorectal cancer [J]. World Journals of Gastroenterology, 2008, 14(39):6052-6059.
|
| [5] |
Elzagheid A, Buhmeida A, Korkeila E, et al. Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma [J].World Journals of Gastroenterology, 2008, 14(24):3866-3871.
|
| [6] |
Kwon C, Cheng P, King IN, et al. Notch post-translationally regulates β-catenin protein in stem and progenitor cells [J]. Nature Cell Biology, 2011, 13(10):1244-1251.
|
| [7] |
Armura S, Matsunaga A, Kitamura T, et al. Reduce level of smoothened supresses intestinal tumorigenesis by down-regulation of Wnt signaling [J]. Gastroenterology, 2009, 137(2):629-638.
|
| [8] |
van den Brink GR, Bleuming SA, Hardwick JC, et al.India Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation [J]. Nature genetics, 2004, 36(3):277-282.
|
| [9] |
Dong GZ, Shim AR, Hyeon JS, et al. Inhibition of Wnt/β-Catenin Pathway by Dehydrocostus Lactone and Costunolide in Colon Cancer Cells [J]. Phytother Res, 2015, 29(5):680-686.
|
| [10] |
Qualtrough D, Buda A, Gaffield W, et al. Hedgehog signalling in colorectal tumour cells: induction of apoptosis with cyclopamine treatment [J]. Int J Cancer, 2004, 110(6):831-837.
|
| [11] |
Fu X, Deng H, Zhao L, et al. Distinct expression patterns of hedgehog ligands between cultured and primary colorectal cancers are associated with aberrant methylation of their promoters [J]. Mol Cell Biochem, 2010, 337(1-2):185-192.
|
| [12] |
Yoshimoto AN, Bernardazzi C, Carneiro AJ, et al. Hedgehog pathway signaling regulates human colon carcinoma HT-29 epithelial cell line apoptosis and cytokine secretion [J]. PLoS One, 2012, 7(9):e45332.
|
| [13] |
Wang H, Li YY, Wu YY, et al. Expression and clinical significance of hedgehog signaling pathway related components in colorectal cancer [J]. Asian Pacific J Cancer Prev, 2012, 13(5):2319-2324.
|
| [14] |
Yuan R, Ke J, Sun L, et al. HES1 promotes metastasis and predicts poor survival in patients with colorectal cancer [J]. Clin Exp Metastasis, 2015, 32(2):169-179.
|
| [15] |
Ozawa T, Kazama S, Akiyoshi T, et al. Nuclear Notch3 expression is associated with tumor recurrence in patients with stage II and III colorectal cancer [J]. Ann Surg Oncol, 2014, 21(8):2650-2658.
|
| [16] |
Dai Y, Wilson G, Huang B, et al. Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer [J]. Cell Death Dis, 2014, 5:e1170.
|
| [17] |
Rodilla V, Villanueva A, Obrador-Hevia A, et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer [J]. Proc Natl Acad Sci U S A, 2009, 106(15):6315-6320.
|
| [18] |
Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis [J]. Gastroenterology, 2008, 135(4):1079-1099.
|
| [19] |
Ilyas M, Efstathiou JA, Straub J, et al. Transforming growth factor beta stimulation of colorectal cancer cell lines: Type II receptor bypass and changes in adhesion molecule expression [J]. Proc Natl Acad Sd USA, 1999, 96(6):3087-3091.
|
| [20] |
Xu Y, Pasche B. TGF-beta signaling alterations and susceptibility to colorectal cancer [J]. Hum Mol Genet, 2007, 16(spec.no.1):R14-R20.
|
| [21] |
Tang Y, Katuri V, Srinvasan R, et al. Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis [J]. Cancer Res, 2005, 65(10):4288-4237.
|
| [22] |
Slattery ML, Lundgreen A, Kadlubar SA, et al. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer [J]. Mol Carcinog, 2013, 52(2):155-66.
|
| [23] |
Wang SW, Hu J, Guo QH, et al. AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway [J]. Oncol Rep, 2014, 32(5):1991-1998.
|
| [24] |
Pandurangan AK, Esa NM. Signal transducer and activator of transcription 3 - a promising target in colitis-associated cancer. Asian Pac J Cancer Prev, 2014, 15(2):551-560.
|
| [25] |
Xiong H, Su WY, Liang QC, et al. Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells [J]. Lab Invest, 2009, 89(6):717-725.
|
| [26] |
Shareef MM, Shamloula MM, Elfert AA, et al. Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis [J]. Arab J Gastroenterol, 2009, 10(1):25-32.
|
| [27] |
Gordiziel C, Bratsch J, Moriggl R, et al. Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma [J]. Br J Cancer, 2013, 109(1):138-46.
|
| [28] |
Lan YT, Jen-Kou L, Lin CH, et al. Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers [J]. J Surg Oncol, 2015, 111(7):905-910.
|
| [29] |
Grabocka E, Pylayeva-Gupta Y, Jones MJ, et al. Wild-Type H-and N-Ras Promote Mutant K-Ras-Driven Tumorigenesis by Modulating the DNA Damage Response [J]. Cancer Cell, 2014, 25(2):243-256.
|
| [30] |
Stec R, Bodnar L, Charkiewicz R, et al. K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoingirinotecan-or oxaliplatin-based chemotherapy [J]. Cancer Biol Ther, 2012, 13(13):1235-1243.
|
| [31] |
Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer [J]. Cancer Res, 2004, 64(21):7678-7681.
|
| [32] |
Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers [J]. Science, 2004, 304(5670):554.
|
| [33] |
Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations [J]. Nat Rev Cancer, 2009, 9(8):550-562.
|
| [34] |
Jang KS, Song YS, Jang SH, et al. Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma [J]. Histopathology, 2010, 56(2):229-239.
|
| [35] |
Sawai H, Yasuda A, Ochi N, et al. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol, 2008, 8:56.
|
| [36] |
Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies [J]. Cancer Res, 2009, 69(5):1851-1857.
|
| [37] |
Prenen H, De Schutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer [J]. Clin Cancer Res, 2009, 15(9):3184-3188.
|
| [38] |
Di Popolo A, Memoli A, Apicella A, et al. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells [J]. Oncogene, 2000, 19(48):5517-5524.
|
| [39] |
Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas [J]. N Engl J Med, 2003, 348(10):891-910.
|
| [40] |
Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials [J]. Lancet, 2010, 376(9754):1741-1750.
|
| [41] |
Peng L, Zhou Y, Wang Y, et al. Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature [J]. PLoS One, 2013, 8(3):e58891.
|
| [42] |
Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival [J]. N Engl J Med, 2012, 367(17):1596-1606.
|
| [43] |
Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer [J]. J Clin Oncol, 2013, 31(34):4297-4305.
|
| [44] |
Li A, Chen H, Lin M, et al. PIK3C2G copy number is associated with clinical outcomes of colorectal cancer patients treated with oxaliplatin [J]. Int J Clin Exp Med, 2015, 8(1):1137-1143.
|